Jump to content

Delucemine

From Wikipedia, the free encyclopedia

Delucemine
Clinical data
ATC code
  • none
Identifiers
  • 3,3-Bis(3-fluorophenyl)-N-methylpropan-1-amine
CAS Number
PubChemCID
ChemSpider
UNII
ChEMBL
CompTox Dashboard(EPA)
Chemical and physical data
FormulaC16H17F2N
Molar mass261.316g·mol−1
3D model (JSmol)
  • CNCCC(C1=CC(=CC=C1)F)C2=CC(=CC=C2)F
  • InChI=1S/C16H17F2N/c1-19-9-8-16(12-4-2-6-14(17)10-12)13-5-3-7-15(18)11-13/h2-7,10-11,16,19H,8-9H2,1H3☒N
  • Key:MUGNLPWYHGOJEG-UHFFFAOYSA-N☒N
☒NcheckY(what is this?)(verify)

Delucemine(NPS-1506) is a drug which acts as anNMDA antagonistand aserotonin reuptake inhibitor,and hasneuroprotectiveeffects.[1][2]It was originally investigated for the treatment ofstrokeand in 2004 was studied as a potentialantidepressant.[3][4][5]

Origin

[edit]

The basic structure of delucemine was based onargiotoxin 636,a NMDA antagonist isolated from the venom of the AraneidArgiope aurantia.[6][7][8]

See also

[edit]

References

[edit]
  1. ^Mueller AL, Artman LD, Balandrin MF, Brady E, Chien Y, Delmar EG, George K, Kierstead A, Marriott TB, Moe ST, Newman MK, Raszkiewicz JL, Sanguinetti EL, van Wagenen BC, Wells D (December 1999). "NPS 1506, a novel NMDA receptor antagonist and neuroprotectant. Review of preclinical and clinical studies".Annals of the New York Academy of Sciences.890(1): 450–7.Bibcode:1999NYASA.890..450M.doi:10.1111/j.1749-6632.1999.tb08023.x.PMID10668449.S2CID5629889.
  2. ^Leoni MJ, Chen XH, Mueller AL, Cheney J, McIntosh TK, Smith DH (December 2000). "NPS 1506 attenuates cognitive dysfunction and hippocampal neuron death following brain trauma in the rat".Experimental Neurology.166(2): 442–9.doi:10.1006/exnr.2000.7513.PMID11085909.S2CID39222349.
  3. ^"NPS Pharmaceuticals Inc, Form 10-Q, Quarterly Report, Filing Date May 17, 2004".secdatabase.com.RetrievedMay 14,2018.
  4. ^CA 2599721,Pyke R, Ceci A, "Pharmaceutical compositions for the treatment and/or prevention of depression"
  5. ^WO 2014015047,Ichinose F, Marutani E, Kida K, "Compositions and methods to treat neurodegenerative diseases"
  6. ^Nentwig W (2013-02-15).Spider Ecophysiology.Springer Science & Business Media.ISBN9783642339899.
  7. ^Oldrati V, Bianchi E, Stöcklin R (February 2013). "Spider Venom Components as Drug Candidates".Spider Ecophysiology.pp. 491–503.doi:10.1007/978-3-642-33989-9_37.ISBN978-3-642-33988-2.
  8. ^Monge-Fuentes V, Gomes FM, Campos GA, Silva Jd, Biolchi AM, Dos Anjos LC, Gonçalves JC, Lopes KS, Mortari MR (August 2015)."Neuroactive compounds obtained from arthropod venoms as new therapeutic platforms for the treatment of neurological disorders".The Journal of Venomous Animals and Toxins Including Tropical Diseases.21(31): 31.doi:10.1186/s40409-015-0031-x.PMC4529710.PMID26257776.